Lung transplant can extend survival in some patients with stage 4 lung cancer, according to a study published July 8 in JAMA.
Researchers and physicians from Chicago-based Northwestern Medicine analyzed data from 404 adult patients with end-stage pulmonary disease, including 98 with stage 4 lung cancer, between September 2021 and June 2025 to assess outcomes associated with lung transplant.
Here are five things to know from the study:
- Of the 98 patients with stage 4 lung cancer, 17 received a lung transplant and 81 received medical therapy alone because of logistical, financial or geographic factors.
- After the study period, all 17 transplant patients were alive but fewer than half of similar patients who received medical therapy only were alive.
- Patients with stage 4 lung cancer who received a lung transplant had a 100% one-year posttransplant survival rate while the one-year survival rate among patients with stage 4 lung cancer who did not receive a lung transplant was 41%.
- Patients without cancer who received a lung transplant had an 88% one-year posttransplant survival rate.
- The study was conducted as part of Northwestern’s Double Lung Transplant Registry for Lung-Limited Malignancies program. Also known as the DREAM registry, the program tests whether lung transplantation can be used for patients with organ-confined, treatment-resistant lung cancer who are at risk of dying from respiratory failure.
Read the full study here.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
